Market Closed -
Other stock markets
|
Pre-market 07:33:07 am | |||
2.37 USD | +11.79% | 2.27 | -4.22% |
May. 07 | Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell | MT |
May. 07 | Top Premarket Gainers | MT |
Financials (USD)
Sales 2024 * | 321M | Sales 2025 * | 295M | Capitalization | 449M |
---|---|---|---|---|---|
Net income 2024 * | -79M | Net income 2025 * | -23M | EV / Sales 2024 * | 0.7 x |
Net cash position 2024 * | 223M | Net cash position 2025 * | 342M | EV / Sales 2025 * | 0.36 x |
P/E ratio 2024 * |
21.5
x | P/E ratio 2025 * |
-19.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Esperion Therapeutics, Inc.
1 day | +11.79% | ||
1 week | +20.30% | ||
Current month | +20.30% | ||
1 month | -26.85% | ||
3 months | -9.89% | ||
6 months | +130.10% | ||
Current year | -20.74% |
Managers | Title | Age | Since |
---|---|---|---|
Sheldon Koenig
CEO | Chief Executive Officer | 58 | 20-12-14 |
Director of Finance/CFO | 38 | 19-12-31 | |
JoAnne Foody
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-06-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 22-04-27 | |
J. Carroll
CHM | Chairman | 74 | 22-05-31 |
Alan Fuhrman
BRD | Director/Board Member | 67 | 20-03-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | +3.48% | - | |
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 2.37 | +11.79% | 45,902,476 |
24-05-06 | 2.12 | +1.92% | 6,816,851 |
24-05-03 | 2.08 | +0.97% | 5,530,903 |
24-05-02 | 2.06 | +0.98% | 2,961,932 |
24-05-01 | 2.04 | +3.55% | 3,150,248 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.74% | 449M | |
+33.43% | 700B | |
+26.43% | 569B | |
-5.12% | 358B | |
+19.59% | 330B | |
+4.89% | 287B | |
+14.32% | 236B | |
+5.79% | 202B | |
-9.49% | 197B | |
+4.26% | 161B |
- Stock Market
- Equities
- ESPR Stock